Pharmacokinetic and Pharmacodynamic Study of S-1 in Patients With Digestive Organ Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
S-1 is a novel oral fluorouracil antitumor drug that consists of tegafur which is a prodrug
of 5-fluorouracil (5-FU); 5-chloro-2,4-dihydropyridine (CDHP), which inhibits
dihydropyrimidine dehydrogenase (DPD) activity; and potassium oxonate (Oxo), which reduces
gastrointestinal toxicity. 5-FU is metabolized by CYP2A6 and DPD. In this study, the
researchers investigate the influences of differences in activities of CYP2A6 and DPD on
pharmacokinetics and pharmacodynamics of S-1 and clinical outcomes in digestive organ cancer
patients treated with S-1.